Pharmacyclics, Inc. (PCYC) - Financial and Strategic SWOT Analysis Review

Summary

Pharmacyclics, Inc. (Pharmacyclics) is a clinical-stage biopharmaceutical company. The company discovers and develops innovative small-molecule drugs for the treatment of immunological disorders and cancer. Pharmacyclics’ drug candidates are synthetic small-molecules that target key biochemical pathways that are associated with human diseases that have high unmet clinical need. Its clinical pipeline includes three proprietary drug candidates under development and several preclinical molecules in lead optimization.

Pharmacyclics, Inc. Key Recent Developments

Feb 14, 2013: Pharmacyclics Reports Revenue Of $58m In Q2 Fiscal 2013
Nov 05, 2012: Pharmacyclics Reports Revenue Of $102.7m In Q1 Fiscal 2013
Sep 05, 2012: Pharmacyclics Reports Revenue Of $2.1m In Q4 Fiscal 2012
May 10, 2012: Pharmacyclics Reports Revenue Of $1.9m In Q3 Fiscal 2012
Feb 09, 2012: Pharmacyclics Reports Revenue Of $77.9m In Q2 Fiscal 2012GDPH81653FSA

This comprehensive SWOT profile of Pharmacyclics, Inc. provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs. SHOW LESS READ MORE >

List of Tables
List of Figures
Section 1 - About the Company
Pharmacyclics, Inc. - Key Facts
Pharmacyclics, Inc. - Key Employees
Pharmacyclics, Inc. - Key Employee Biographies
Pharmacyclics, Inc. - Major Products and Services
Pharmacyclics, Inc. - Pharmaceutical Pipeline Products Data
Pharmacyclics, Inc., Pipeline Products by Therapy Area
Pharmacyclics, Inc., Pipeline Products by Development Phase
Pharmacyclics, Inc. - History
Pharmacyclics, Inc. - Company Statement
Pharmacyclics, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Pharmacyclics, Inc. - Business Description
Pharmacyclics, Inc. - Corporate Strategy
Pharmacyclics, Inc. - SWOT Analysis
SWOT Analysis - Overview
Pharmacyclics, Inc. - Strengths
Strength - Strong Product Pipeline
Strength - Strong Intellectual Property
Strength - Strong Liquidity
Strength - Increase in Profitability Indicators
Pharmacyclics, Inc. - Weaknesses
Weakness - Lack of Product Revenue
Pharmacyclics, Inc. - Opportunities
Opportunity - Market Potential: Oncology
Opportunity - Orphan Drug Designation
Opportunity - Collaboration and Agreements
Pharmacyclics, Inc. - Threats
Threat - Competitive Environment
Threat - Tightening of the FDA’s Regulatory Oversight
Threat - Uncertainties from Clinical R&D Activities
Pharmacyclics, Inc. - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Pharmacyclics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
Pharmacyclics, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013
Pharmacyclics, Inc., Recent Deals Summary
Section 5 – Company’s Recent Developments
Pharmacyclics, Inc., Recent Developments
Feb 14, 2013: Pharmacyclics Reports Revenue Of $58m In Q2 Fiscal 2013
Nov 05, 2012: Pharmacyclics Reports Revenue Of $102.7m In Q1 Fiscal 2013
Sep 05, 2012: Pharmacyclics Reports Revenue Of $2.1m In Q4 Fiscal 2012
May 10, 2012: Pharmacyclics Reports Revenue Of $1.9m In Q3 Fiscal 2012
Feb 09, 2012: Pharmacyclics Reports Revenue Of $77.9m In Q2 Fiscal 2012
Section 6 – Appendix
Methodology
Ratio Definitions
About Us
Contact Us
Disclaimer

List of Tables
Pharmacyclics, Inc., Key Facts
Pharmacyclics, Inc., Key Employees
Pharmacyclics, Inc., Key Employee Biographies
Pharmacyclics, Inc., Major Products and Services
Pharmacyclics, Inc., Number of Pipeline Products by Therapy Area
Pharmacyclics, Inc., Number of Pipeline Products by Development Stage
Pharmacyclics, Inc., Pipeline Products By Therapy Area and Development Phase
Pharmacyclics, Inc., History
Pharmacyclics, Inc., Subsidiaries
Pharmacyclics, Inc., Key Competitors
Pharmacyclics, Inc., Ratios based on current share price
Pharmacyclics, Inc., Annual Ratios
Pharmacyclics, Inc., Interim Ratios
Pharmacyclics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
Pharmacyclics, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013
Pharmacyclics, Inc., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Pharmacyclics, Inc., Pipeline Products by Therapy Area
Pharmacyclics, Inc., Pipeline Products by Development Phase
Pharmacyclics, Inc., Performance Chart (2008 - 2012)
Pharmacyclics, Inc., Ratio Charts
Pharmacyclics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
Pharmacyclics, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2007 to YTD 2013

Novartis Vaccines and Diagnostics, Inc.
Ambrilia Biopharma Inc.
Advanced Life Sciences holdings, Inc.
Aphton Corporation
Aphios Corporation